On May 30, 2022 Hoffmann-La Roche reported to invite investors and analysts to participate in our virtual event on Monday, 6 June 2022, highlighting Roche data presented during the congress scientific program from June 3 – 7 2022 and our early-stage oncology portfolio (Press release, Hoffmann-La Roche, MAY 30, 2022, View Source [SID1234615225]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CEST on the day of the event. > click here

Agenda

Oncology late-stage portfolio update
Elena Bernedo-Arzac, SVP, Oncology Therapeutic Area Head

Key Data at ASCO (Free ASCO Whitepaper) 2022
– Glofitamab pivotal Ph1b data in 3L+DLBCL
– Polivy Asian sub-population data from Ph3 POLARIX in 1L DLBCL
Ginna Laporte, MD – VP, Global Head Lymphoma/CLL Clinical Development

Oncology early R&D update
Johanna Bendell, M.D., Head of Roche Pharma Research and Early Development (pRED) Oncology
Andy Chan, M.D., Ph.D. Senior Vice President, Research Biology, Genentech Research & Early Development (gRED)